Format

Send to

Choose Destination
Anticancer Res. 2018 Mar;38(3):1267-1278.

Update on Surgical Management of Small Bowel Neuroendocrine Tumors.

Author information

1
Department of Surgery, Duke University Medical Center, Duke University, Durham, NC, U.S.A. dimitrios.moris@duke.edu.
2
First Department of Surgery, National and Kapodistrian University of Athens, Medical School, Laiko Hospital, Athens, Greece.
3
Second Department of Surgery, National and Kapodistrian University of Athens, Aretaieio University Hospital, Athens, Greece.
4
Department of Surgery, Ioannina University Hospital, Ioannina, Greece.
5
Department of Surgery, Duke University Medical Center, Duke University, Durham, NC, U.S.A.

Abstract

The widespread use of endoscopy and imaging in combination with the continuous update of the staging systems for neuroendocrine tumors has led to an increase in the incidence of small intestinal neuroendocrine tumors (si-NENs) globally. Despite high survival rates, severe complications may occur even in early stages due to the anatomic location of the primary site and the desmoplastic reaction. Surgery plays a central role in the management of patients with si-NENs. Excision of locoregional disease along with extensive lymph node dissection should be performed in fit patients, even in the presence of metastases. Multimodality treatment of liver metastases includes hepatectomy, ablative techniques and liver transplantation. Hormone therapy with somatostatine analogs is of high importance for symptomatic control; special caution should be exercised both pre- and intra-operatively. A multidisciplinary approach is essential in order to provide personalized therapeutics for patients with si-NENs. Clinical research and specialization in this field should be further encouraged.

KEYWORDS:

Neuroendocrine tumors; cancer; ileum; jejunum; review; small intestine

PMID:
29491050
DOI:
10.21873/anticanres.12349
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center